PCM
DNLI icon

Prelude Capital Management’s Denali Therapeutics DNLI Stock Holding History

Prelude Capital Management’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-15,940
Closed -$223K – 1196
2025
Q2 		$223K Buy
+15,940
New +$224K 0.02% 754
2024
Q3 		– Sell
-10,343
Closed -$240K – 1345
2024
Q2 		$240K Sell
10,343
-26
-0.3% -$499 0.02% 905
2024
Q1 		$213K Buy
10,369
+25
+0.2% +$470 0.01% 1077
2023
Q4 		$222K Buy
10,344
+40
+0.4% +$792 0.01% 899
2023
Q3 		$213K Sell
10,304
-335
-3% -$8.5K 0.01% 867
2023
Q2 		$314K Sell
10,639
-700
-6% -$19.7K 0.02% 621
2023
Q1 		$261K Buy
11,339
+3,996
+54% +$110K 0.02% 712
2022
Q4 		$204K Buy
+7,343
New +$218K 0.01% 961
2022
Q1 		– Sell
-9,610
Closed -$429K – 1917
2021
Q4 		$429K Buy
9,610
+3,598
+60% +$170K 0.01% 1110
2021
Q3 		$303K Buy
6,012
+1,029
+21% +$58K 0.01% 1131
2021
Q2 		$391K Buy
+4,983
New +$308K 0.01% 1072
2021
Q1 		– Sell
-2,950
Closed -$247K – 1604
2020
Q4 		$247K Sell
2,950
-6,150
-68% -$372K 0.01% 1010
2020
Q3 		$326K Sell
9,100
-1,809
-17% -$54.5K 0.02% 533
2020
Q2 		$264K Buy
+10,909
New +$256K 0.01% 653
2019
Q2 		– Sell
-4,229
Closed -$98K – 1768
2019
Q1 		$98K Buy
4,229
+2,252
+114% +$47.1K 0.01% 936
2018
Q4 		$41K Buy
+1,977
New +$35.9K ﹤0.01% 1150

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prelude Capital Management's DNLI Position: Q3 2025 in Review

Prelude Capital Management sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 15,940 shares — an estimated $223K sold.

Prelude Capital Management first reported a position in DNLI in Q4 2018 and held it in 16 quarters. The position peaked at $429K in Q4 2021. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Prelude Capital Management reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 15,940 Denali Therapeutics shares in Q3 2025, an estimated $223K.
  • Prelude Capital Management first reported a position in Denali Therapeutics in Q4 2018 and held it in 16 quarters.
  • Prelude Capital Management's Denali Therapeutics position peaked at $429K in Q4 2021.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.